Supernus Provides Business Update

ROCKVILLE, Md., Nov. 14, 2016 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today provided the following business update.

Commercial Update

Third quarter 2016 product prescriptions for Trokendi XR ® and Oxtellar XR ®, as reported by IMS, totaled 131,408, a 30.4% increase over the third quarter of 2015.
    Prescriptions      
  Q3 2016 Q3 2015   Change %  
           
Trokendi XR     99,049     75,104       31.9 %  
Oxtellar XR     32,359     25,666       26.1 %  
             
Total     131,408     100,770       30.4 %  

Source:  IMS

If you liked this article you might like

MediWound Shares Lower After Pricing Stock Offering - Biotech Movers

UPS, McKesson, Chegg and More: 'Mad Money' Lightning Round

Investors Should Ignore Washington: Cramer's 'Mad Money' Recap (Tuesday 7/18/17)

10 Sectors That Will Profit Big-Time From Oil's Crash

Biotech Movers: Anika Up on Strong Analyst Ratings